drugset

drugset / Trial / NCT06516484

Ropustin for Refractory Aplastic Anaemia After Radiotherapy - a Single-centre, Prospective, Open-label, Single-arm Study

NCT06516484 ↗

Phase 4 Not yet recruiting 40 enrolled Peking Union Medical College Hospital

NaSingle-groupOpen-labelTreatment

Summary

To investigate the efficacy and safety of roprostin in the treatment of refractory AA after radiotherapy.

Timeline

Start: 2024-07-30
Primary completion: 2025-07-31
Completion: 2025-12-31

Publications

Background Kuter DJ. The biology of thrombopoietin and thrombopoietin receptor agonists. Int J Hematol. 2013 Jul;98(1):10-23. doi: 10.1007/s12185-013-1382-0. Epub 2013 Jul 3.
Background Lee JW, Lee SE, Jung CW, Park S, Keta H, Park SK, Kim JA, Oh IH, Jang JH. Romiplostim in patients with refractory aplastic anaemia previously treated with immunosuppressive therapy: a dose-finding and long-term treatment phase 2 trial. Lancet Haematol. 2019 Nov;6(11):e562-e572. doi: 10.1016/S2352-3026(19)30153-X. Epub 2019 Aug 29.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Romiplostim	Peptide	20 ug/kg	Subcutaneous

Indications